Cognition Therapeutics

CGTX

Market cap $130M

Overview Fund Activity

1.47 USD

-0.14

8.7%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

1.53

+0.06

4.08%

1 day

-8.7%

5 days

-41.43%

1 month

-1.34%

3 months

425%

6 months

228.93%

Year to date

103.29%

1 year

149.87%

5 years

-88.49%

10 years

-88.49%

About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Employees: 25

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0.63% less ownership

Funds ownership: 18.76% [Q1] → 18.13% (-0.63%) [Q2]

4% less funds holding

Funds holding: 51 [Q1] → 49 (-2) [Q2]

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

28% less capital invested

Capital invested by funds: $4.89M [Q1] → $3.51M (-$1.38M) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3

104% upside

Avg. target

$3.5

138% upside

High target

$4

172% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Chardan Capital Daniil Gataulin	$4	Buy Maintained	8 Aug 2025
HC Wainwright & Co. Raghuram Selvaraju	$3	Buy Reiterated	26 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about CGTX published over the past 30 days

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START' Study has reached the 75% enrollment mark. The START Study is enrolling approximately 540 individuals with mild cognitive impairment (MCI) and early Alzheimer's disease who will be treated with zervimesine (CT1812) or placebo for 18 months. Cognition is conducting the study in collaboration with the Alzheimer's Clinical Trials Consortium (ACTC) with funding from the National Institute of Aging (NIA) at the National Institutes of Health.

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

The Motley Fool

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

While last month ended up being a decent one for the Nasdaq Composite, it was downright fantastic for a handful of Nasdaq-listed names. Here's a rundown of the Nasdaq Composite's five-best performing stocks that blew the index's 1.6% August gain out of the water.

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously announced registered direct offering of 14,700,000 shares of common stock at a purchase price of $2.05 per share. Gross proceeds from the offering were approximately $30 million, before deducting placement agent fees and other offering expenses.

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders - PURCHASE, N.Y., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that it has entered into a securities purchase agreement for the purchase and sale of 14,700,000 shares of its common stock pursuant to a registered direct offering.

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, was notified by The Nasdaq Listing Qualifications Staff (“Nasdaq”) that the Company has regained compliance with the exchange's continued listing standard for minimum share price under Rule 5550(a)(2) (the “Bid Price Rule”).

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" Rating

I rate Cognition Therapeutics a "Strong Buy" due to FDA alignment on two pivotal phase 3 trials zervimesine in mild-to-moderate Alzheimer's patients with low p-tau217; Successful results means NDA filing. Zervimesine showed a remarkable 95% slowing of cognitive decline in the low-ptau217 biomarker-defined subgroup, supporting a precision medicine approach and strong phase 3 prospects. The company is well-financed through government grants and has multiple funding options, with operational funding into Q2 2026, reducing near-term dilution risk.

Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" Rating

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

- Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, received final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the end-of-Phase 2 meeting that was conducted on July 9, 2025.

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

The Motley Fool

Cognition (CGTX) Q2 Grant Income Jumps

Cognition Therapeutics (CGTX -4.78%), a clinical-stage biotechnology firm focused on developing therapies for neurodegenerative diseases, released its earnings for Q2 2025 on August 7, 2025. The company reported a GAAP net loss per share of $(0.11) for Q2 2025, missing consensus estimates by $(0.005)

Cognition (CGTX) Q2 Grant Income Jumps

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

- Zervimesine's impact on debilitating DLB behavioral symptoms highlighted in podium presentation - - Plasma p-tau217 levels can identify Alzheimer's patients most likely to benefit from zervimesine treatment - - Plasma and CSF biomarkers support zervimesine's impact on Alzheimer's disease biology -

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL Study In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL Study

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

See News Rankings

Charts implemented using Lightweight Charts™